Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Tabrecta
|
| gptkbp:CASNumber |
1029712-80-8
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C24H25FN6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
capmatinib
|
| gptkbp:indication |
MET exon 14 skipping mutation
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MET inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting fatigue peripheral edema increased creatinine |
| gptkbp:target |
MET proto-oncogene
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:c-Met
gptkb:Tabrecta |
| gptkbp:bfsLayer |
6
|